Director/PDMR Shareholding
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Colleen Pythian, Director of Quality and Regulation and a PDMR, acquired 25,644 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at a price of 9.70p per share today.
Following these purchases, Colleen Pythian's total beneficial interest is 25,644 Ordinary Shares, 0.07% of the issued share capital of the Company.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
a. |
Name |
Colleen Pythian
|
||||
2. |
Reason for the notification |
|||||
a. |
Position/status |
Director of Quality & Regulation |
||||
a. |
Initial notification /Amendment |
Initial notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a. |
Name |
genedrive plc |
||||
b. |
LEI |
213800ZYODIRZ87Y4K14 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
a. |
Description of the Financial instrument, type of instrument Identification code |
Ordinary shares of 1.5 pence each
GB00B1VKB244 |
||||
b. |
Nature of the transaction |
Purchase |
||||
c. |
Price(s) and volume(s) |
|
||||
d. |
Aggregated information · Aggregated volume · Price
|
N/A
|
||||
e. |
Date of the transaction |
2020-02-11 |
||||
f. |
Place of the transaction |
London Stock Exchange, AIM |
For further details please contact:
genedrive plc |
+44 (0)161 989 0245 |
|
David Budd: CEO / Matthew Fowler: CFO |
|
|
|
|
|
Peel Hunt LLP (Nominated Adviser and Joint Broker) |
+44 (0)207 418 8900 |
|
James Steel / Oliver Jackson |
|
|
|
|
|
Stanford Capital Partners Limited (Joint Broker) |
+44 (0)20 3815 8880 |
|
Patrick Claridge / John Howes |
|
|
|
|
|
Walbrook PR Ltd (Media Relations & Investor Relations) |
+44 (0)20 7933 8780 or genedrive@walbrookpr.com |
|
Paul McManus / Anna Dunphy |
+44 (0)7980 541 893 / +44 (0)7876 741 001 |
|